Besides building UCB's epilepsy position, the deal "marks a strategic expansion into regenerative me...
UCB pays $650M+ for Neurona, marking 'strategic expansion' into regenerative medicine
Besides building UCB's epilepsy position, the deal "marks a strategic expansion into regenerative medicine and advanced therapies," the company said.
Author: Fierce Biotech
Read Original Article